6-tert-butyl-2-(trifluoromethyl)pyrimidin-4-amine | 1374771-54-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 6-tert-butyl-2-(trifluoromethyl)pyrimidin-4-amine
• CAS: 1374771-54-6
• 化学式: C₉H₁₂F₃N₃
• 分子量: 219.21
• InChiKey: OORDQKVLRJIBCB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  51.8
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• [EN] FGFR2 MODULATORS<br/>[FR] MODULATEURS DE FGFR2
  申请人：EXELIXIS INC

  公开号：WO2012061337A1

  公开（公告）日：2012-05-10

  A compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein:R3a, R2, R3b, R4b, L1, G and J are as defined in the specification, pharmaceutical compositionsthereof, and methods of use thereof.

  一个由化学式（I）组成的化合物，或其药学上可接受的盐，其中：R3a、R2、R3b、R4b、L1、G和J的定义如规范中所述，以及其药物组成物和使用方法。
• PqsR INVERSE AGONISTS
  申请人：HELMHOLTZ-ZENTRUM FÜR INFEKTIONSFORSCHUNG GMBH

  公开号：US20210353606A1

  公开（公告）日：2021-11-18

  The present invention relates to a compound according to general formula (I), which acts as an inhibitor of PqsR (the currently only known receptor for the Pseudomonas Quinolone Signal (PQS)); to a pharmaceutical composition containing one or more of the compound(s) of the invention; to a combination preparation containing at least one compound of the invention and at least one further active pharmaceutical ingredient; and to uses of said compound(s), including the use as a medicament, e.g. the use in the treatment or prophylaxis of a bacterial infection, especially a Pseudomonas aeruginosa or Burkholderia infection.
• [EN] PqsR INVERSE AGONISTS<br/>[FR] AGONISTES INVERSES DE PQSR
  申请人：HELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH

  公开号：WO2020007938A1

  公开（公告）日：2020-01-09

  The present invention relates to a compound according to general formula (I), which acts as an inhibitor of PqsR (the currently only known receptor for the Pseudomonas Quinolone Signal (PQS)); to a pharmaceutical composition containing one or more of the compound(s) of the invention; to a combination preparation containing at least one compound of the invention and at least one further active pharmaceutical ingredient; and to uses of said compound(s), including the use as a medicament, e.g. the use in the treatment or prophylaxis of a bacterial infection, especially a Pseudomonas aeruginosa or Burkholderia infection.